Erratum to: Rheumatol Ther (2016) 3:5–29 DOI 10.1007/s40744-016-0031-5
In the original version, the second paragraph (last sentence) of the section “Efficacy of Secukinumab in Patient Subgroups” under heading FUTURE 1 AND FUTURE 2, a value is incorrect. The correct sentence should read as:
The Week 52 observed data were 62.1% for secukinumab 300 mg, 48.3% for secukinumab 150 mg, and 63.2% for secukinumab 75 mg (Fig. 12b).
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40744-016-0031-5.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Mease, P., McInnes, I.B. Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther 3, 363 (2016). https://doi.org/10.1007/s40744-016-0039-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-016-0039-x